AbbVie Inc. (NYSE:ABBV) might not like it if biosimilars get introduced in the US as this could directly impact the sales for its best-selling biotech drug Humira, which accounts for almost 65% of the company's revenue. The drug generated sales of $9.2 billion in the first three quarters of 2014 and costs $1,000 a vial in the US.
AbbVie Inc. (NYSE:ABBV) might not like it if biosimilars get introduced in the US as this could directly impact the sales for its best-selling biotech drug Humira, which accounts for almost 65% of the company's revenue. The drug generated sales of $9.2 billion in the first three quarters of 2014 and costs $1,000 a vial in the US.
Share this Article
Comment on this Article
Recommended
Please to comment